Toggle Main Menu Toggle Search

Open Access padlockePrints

Alpha-synuclein glycation and the action of anti-diabetic agents in Parkinson's disease

Lookup NU author(s): Professor Tiago OuteiroORCiD



This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).


© 2018 - IOS Press and the Authors. All Rights Reserved. Parkinson's disease (PD) is a neurodegenerative disorder with complex etiology and variable pathology. While a subset of cases is associated with single-gene mutations, the majority originates from a combination of factors we do not fully understand. Thus, understanding the underlying causes of PD is indispensable for the development of novel therapeutics. Glycation, the non-enzymatic reaction between reactive dicarbonyls and amino groups, gives rise to a variety of different reaction products known as advanced glycation end products (AGEs). AGEs accumulate over a proteins life-Time, and increased levels of glycation reaction products play a role in diabetic complications. It is now also becoming evident that PD patients also display perturbed sugar metabolism and protein glycation, including that of alpha-synuclein, a key player in PD. Here, we hypothesize that anti-diabetic drugs targeting the levels of glycation precursors, or promoting the clearance of glycated proteins may also prove beneficial for PD patients.

Publication metadata

Author(s): Konig A, Miranda HV, Outeiro TF

Publication type: Review

Publication status: Published

Journal: Journal of Parkinson's Disease

Year: 2018

Volume: 8

Issue: 1

Pages: 33-43

Online publication date: 17/02/2018

Acceptance date: 17/01/2018

ISSN (print): 1877-7171

ISSN (electronic): 1877-718X

Publisher: IOS Press


DOI: 10.3233/JPD-171285